₹798
▼ -0.32 -0.04%
29 Jul 2026
NSE Listed · Healthcare
Krishna Institute of Medical Sciences Limited (KIMS)
20-day avg volume: 5.0L shares
- Revenue grew 29% YoY.
- Stock trades at a high P/E of 131.
- High debt relative to equity.
| Metric | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹688 Cr | ₹777 Cr | ₹772 Cr | ₹797 Cr | ₹872 Cr | ₹961 Cr | ₹998 Cr | ₹1,075 Cr |
| EBITDA | ₹145 Cr | ₹182 Cr | ₹160 Cr | ₹150 Cr | ₹146 Cr | ₹142 Cr | ₹125 Cr | ₹131 Cr |
| Net Profit | ₹87 Cr | ₹107 Cr | ₹89 Cr | ₹102 Cr | ₹79 Cr | ₹67 Cr | ₹53 Cr | ₹43 Cr |
| EPS | — | — | — | — | — | — | — | — |
| Metric | Sept 2024 | Dec 2024 | Mar 2025 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹363 Cr | ₹348 Cr | ₹3,067 Cr | ₹346 Cr | ₹373 Cr | ₹430 Cr | ₹442 Cr | ₹456 Cr |
| EBITDA | ₹104 Cr | ₹109 Cr | ₹638 Cr | ₹118 Cr | ₹92 Cr | ₹104 Cr | ₹119 Cr | ₹123 Cr |
| Net Profit | ₹72 Cr | ₹77 Cr | ₹385 Cr | ₹94 Cr | ₹59 Cr | ₹64 Cr | ₹73 Cr | ₹66 Cr |
| EPS | — | — | 9.61 | — | — | — | — | — |
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹958 Cr | ₹1,118 Cr | ₹1,196 Cr | ₹1,436 Cr | ₹1,907 Cr | ₹2,941 Cr | ₹3,852 Cr | ₹5,736 Cr |
| Total Liabilities | ₹1,096 Cr | ₹552 Cr | ₹584 Cr | ₹560 Cr | ₹497 Cr | ₹1,003 Cr | ₹1,759 Cr | ₹3,317 Cr |
| Equity | ₹-138 Cr | ₹566 Cr | ₹611 Cr | ₹876 Cr | ₹1,411 Cr | ₹1,938 Cr | ₹2,093 Cr | ₹2,419 Cr |
| Total Debt | — | — | — | — | — | — | — | — |
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating | ₹135 Cr | ₹165 Cr | ₹255 Cr | ₹394 Cr | ₹451 Cr | ₹529 Cr | ₹661 Cr | ₹723 Cr |
| Investing | ₹-64 Cr | ₹-110 Cr | ₹-125 Cr | ₹-354 Cr | ₹-412 Cr | ₹-547 Cr | ₹-753 Cr | ₹-1,116 Cr |
| Financing | ₹-39 Cr | ₹-27 Cr | ₹-44 Cr | ₹10 Cr | ₹61 Cr | ₹20 Cr | ₹217 Cr | ₹543 Cr |
| Free Cash Flow | ₹135 Cr | ₹165 Cr | ₹255 Cr | ₹394 Cr | ₹451 Cr | ₹529 Cr | ₹661 Cr | ₹723 Cr |
Healthcare · Medical Care Facilities
Krishna Institute of Medical Sciences Limited provides medical and health care services under the KIMS Hospitals brand in India. The company offers arthroscopy and shoulder, cardiology, cardiothoracic and cardiovascular, organ transplant, medical and surgical gastroenterology, hepatology, orthopaedic, neurology, neurosurgery, nephrology, urology, oncology, pediatric, neonatology, obstetrics and gynaecology, fertility, dental science, emergency and critical care, vascular, rehabilitation and physiotherapy services. It also provides pulmonology, diagnostic and imaging, ophthalmology, ENT, rheumatology and clinical immunology, internal medicine, interventional radiology, diabetology, endocrinology, general surgery, infectious disease, dermatology, thoracic surgery, psychiatry, plastic and reconstructive surgery, transfusion medicine, clinical psychology, anesthesiology, and tele medicine services. In addition, the company operates clinical immunology allergy, bone marrow transplantation, hair transplant, andrology, fertility, alzheimer, arthroscopy, bone and joint, breast, dialysis, female urology, IUI, IVF, joint replacement, kidney health and transplant, ICU, spine, stroke, TAVR/TAVI, hepatobiliary surgery, and trauma centers, as well as pain and wellness clinics. Further, it provides bariatric, thoracic, oral maxillofacial, and endovascular surgery services. Krishna Institute of Medical Sciences Limited was incorporated in 1973 and is based in Secunderabad, India.
www.kimshospitals.com ↗As of 2026-06-30
Quarterly — figures in %. Latest 12 quarters.
| Period | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 38.8% | 38.8% | 38.8% | 38.8% | 38.8% | 38.8% | 38.8% | 34.1% | 34.1% | 34.1% | 34.1% | 32.5% |
| FIIs | 14.2% | 15.3% | 16.7% | 17.8% | 15.9% | 15.7% | 15.4% | 15.5% | 15% | 14.3% | 14.6% | 14.7% |
| DIIs | 34.8% | 31.6% | 33.1% | 32.1% | 32.3% | 32% | 32% | 31.7% | 32.1% | 32.7% | 32.5% | 34.4% |
| Public | 12.1% | 14.3% | 11.3% | 11.2% | 13% | 13.5% | 13.8% | 18.7% | 18.7% | 18.8% | 18.8% | 18.3% |
| Promoter Pledge | 16.2% | 16.1% | 16.1% | 15.8% | 15.4% | 12.1% | 12% | 0% | 0% | 3.7% | 10.3% | 10.3% |
| No. of Shareholders | 66,957 | 71,014 | 69,092 | 69,063 | 77,617 | 95,468 | 1,01,895 | 1,08,955 | 1,04,872 | 1,01,599 | 93,333 | 94,730 |
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202503 | — | — | — | — |
| Name | Category | Stake | Shares |
|---|---|---|---|
| Bhaskara Rao Bollineni | Shareholding of Promoter and Promoter Group | 25% | 10.51 Cr |
| Bluebridge Capital Private Limited | Shareholding of Promoter and Promoter Group | 5.8% | 2.42 Cr |
| Sbi Small Cap Fund | Public Shareholding | 5.2% | 2.17 Cr |
| Axis Mutual Fund Trustee Limited A/c Axis Mutual Fund A/c Axis Small Cap Fund | Public Shareholding | 4.5% | 1.89 Cr |
| Hdfc Small Cap Fund | Public Shareholding | 4% | 1.67 Cr |
| Bollineni Seenaiah Naidu | Public Shareholding | 3.9% | 1.65 Cr |
| Kotak Small Cap Fund | Public Shareholding | 3.6% | 1.52 Cr |
| Invesco India Flexi Cap Fun | Public Shareholding | 3.5% | 1.49 Cr |
| Amansa Holdings Private Limited | Public Shareholding | 2.2% | 94,09,513 |
| Nippon Life India Trustee Ltd-a/c Nippon India Small Cap Fund | Public Shareholding | 2% | 81,94,799 |
| Lilac Investments Limited | Public Shareholding | 1.9% | 78,50,000 |
| Sbi Life Insurance Co. Ltd | Public Shareholding | 1.7% | 71,99,780 |
| Rajyasri Bollinen | Shareholding of Promoter and Promoter Group | 1.6% | 68,70,015 |
| Tata Aia Life Insurance Co Ltd-whole Life Mid Cap Equity Fund-ulif 009 04/01/07 Wle 110 | Public Shareholding | 1.6% | 66,07,502 |
| Nomura India Investment Fund Mother Fund | Public Shareholding | 1.5% | 62,80,144 |
| Hdfc Life Insurance Company Limited | Public Shareholding | 1.3% | 54,15,380 |
| Venkata Krishna Kumar Kodali | Public Shareholding | 1.2% | 50,52,800 |
| Mirae Asset Small Cap Fund | Public Shareholding | 1% | 43,68,932 |
| Abhinay Bollineni | Shareholding of Promoter and Promoter Group | 0.1% | 2,36,495 |
| Adwik Bollineni | Shareholding of Promoter and Promoter Group | 0% | 40,640 |
| Sweata Raavi | Shareholding of Promoter and Promoter Group | 0% | 39,225 |
| Bharas Ventures Llp | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Holder | Pledged Shares | % of Holding | As of |
|---|---|---|---|
| Bhaskara Rao Bollineni | 1.40 Cr | 13.3% | 2026-06-30 |
| Name | Designation | Year |
|---|---|---|
| Bhaskara Rao Bollineni | CMD & Director. | 2025 |
| Abhinay Bollineni | Executive Director & CEO | 2025 |
| Dandamudi Anitha | WTD & Executive Director | 2025 |
| Adwik Bollineni | Non Executive Director | 2025 |
| Saumen Chakraborty | Independent Non Exe. Director | 2025 |
| Ratna Kishore Kaza | Independent Non Exe. Director | 2025 |
| J V Ramudu | Independent Non Exe. Director | 2025 |
| Y Prameela Rani | Independent Non Exe. Director | 2025 |
| Suresh Natwarlal Patel | Independent Non Exe. Director | 2025 |
| Nagajayanthi Raghavendra Das Juttur | Company Sec. & Compli. Officer | 2025 |
| Segment | Revenue | Share |
|---|---|---|
| Hospital Services | ₹349 Cr | 99.8% |
| Electricity Sales | ₹1 Cr | 0.2% |
| Region | Revenue | Share |
|---|---|---|
| India | ₹1,347 Cr | 100% |
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2025 | ₹2 | 95 | 80 | 80 |
| Type | Date | Value | Remark |
|---|---|---|---|
| forthcoming | 2026-08-03 | Board Meetings | — |
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2025 | 1,733 | 0 | 0 | 12 | 52 | 1,797 |
| 2025 | 1,674 | 0 | 0 | 0 | 45 | 1,719 |
| 2025 | 2 | 0 | 0 | 12 | 7 | 20 |
30 recent disclosure(s)
3 disclosure(s)
📍 D No 1-8-31/1 Minister's Road, Secunderabad, Telangana, 500003
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search